GC
RCPI

Guggenheim Capital’s ROCK CREEK PHARMACEUTICALS INC COM STK (DE) RCPI Stock Holding History

Guggenheim Capital’s Portfolio RCPI Stock Details RCPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-1,278
Closed -$6K – 3121
2014
Q4 		$6K Buy
1,278
+445
+53% +$2.34K ﹤0.01% 3000
2014
Q3 		$6K Buy
+833
New +$8.23K ﹤0.01% 2983

Other funds holding RCPI

GCM
Goldman Capital Management New York $103M AUM 21.37% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TC
Talkot Capital Sausalito, California $73.7M AUM 8.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
KCM
Kempner Capital Management Galveston, Texas $106M AUM 29.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Guggenheim Capital's RCPI Position: Q1 2015 in Review

Guggenheim Capital sold out of ROCK CREEK PHARMACEUTICALS INC COM STK (DE) (RCPI) in Q1 2015, closing a stake of 1,278 shares — an estimated $6K sold.

Guggenheim Capital first reported a position in RCPI in Q3 2014 and held it in 2 quarters. The position peaked at $6K in Q4 2014. 59 funds tracked by Wall St. Rank hold RCPI as of Q1 2015.

  • Guggenheim Capital reported no remaining ROCK CREEK PHARMACEUTICALS INC COM STK (DE) position as of Q1 2015 after selling out during the quarter.
  • Guggenheim Capital sold 1,278 ROCK CREEK PHARMACEUTICALS INC COM STK (DE) shares in Q1 2015, an estimated $6K.
  • Guggenheim Capital first reported a position in ROCK CREEK PHARMACEUTICALS INC COM STK (DE) in Q3 2014 and held it in 2 quarters.
  • Guggenheim Capital's ROCK CREEK PHARMACEUTICALS INC COM STK (DE) position peaked at $6K in Q4 2014.
  • 59 funds tracked by Wall St. Rank held ROCK CREEK PHARMACEUTICALS INC COM STK (DE) as of Q1 2015.

Based on Guggenheim Capital's 13F filing for Q1 2015, filed 15 May 2015.